{{Infobox drug 
 | IUPAC_name        =  
 | image             = Liraglutide.png 
 | alt               =  
 | caption           = NMR structure of liraglutide. PDB entry {{PDB2|4apd}} 
 
 < !-- Clinical data -- > 
 | tradename         = Victoza, Saxenda 
 | Drugs.com         =  
 | MedlinePlus       =  
 | pregnancy_AU      = B3 
 | pregnancy_US      = C 
 | pregnancy_category=  
 | licence_EU = yes 
 | legal_AU = S4 
 | legal_CA = Rx-only 
 | legal_UK = POM 
 | legal_US = Rx-only 
 | routes_of_administration = subcutaneous 
 
 < !-- Pharmacokinetic data -- > 
 | bioavailability   =  
 | protein_bound     =  
 | metabolism        =  
 | elimination_half-life =  
 | excretion         = 
 
 < !-- Identifiers -- > 
 | CAS_number        =  	204656-20-2 
 | ATCvet            =  
 | ATC_prefix        = A10 
 | ATC_suffix        = BJ02 
 | PubChem           = 44147092 
 | IUPHAR_ligand = 1133 
 | DrugBank          = DB06655 
 | ChemSpiderID      = 24571200 
 
 < !-- Chemical data -- > 
 | C=172 | H=265 | N=43 | O=51 
 | molecular_weight  = 3751.202 g/mol 
 | smiles = CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O 
 | StdInChI          = 1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-128(223)193-112(59-64-132(227)228)148(244)180-68-41-40-50-111(154(250)199-116(62-67-135(233)234)155(251)204-120(73-100-44-33-31-34-45-100)160(256)214-140(93(11)19-2)168(264)192-97(15)146(242)201-122(76-103-79-183-108-49-39-38-48-106(103)108)158(254)203-118(72-90(5)6)159(255)212-138(91(7)8)166(262)200-110(52-43-70-182-172(177)178)150(246)184-81-129(224)194-109(51-42-69-181-171(175)176)149(245)187-84-137(237)238)196-144(240)95(13)189-143(239)94(12)191-153(249)115(58-63-127(174)222)195-130(225)82-185-152(248)114(61-66-134(231)232)198-156(252)117(71-89(3)4)202-157(253)119(75-102-54-56-105(221)57-55-102)205-163(259)124(85-216)208-165(261)126(87-218)209-167(263)139(92(9)10)213-162(258)123(78-136(235)236)206-164(260)125(86-217)210-170(266)142(99(17)220)215-161(257)121(74-101-46-35-32-36-47-101)207-169(265)141(98(16)219)211-131(226)83-186-151(247)113(60-65-133(229)230)197-145(241)96(14)190-147(243)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,244)(H,184,246)(H,185,248)(H,186,247)(H,187,245)(H,189,239)(H,190,243)(H,191,249)(H,192,264)(H,193,223)(H,194,224)(H,195,225)(H,196,240)(H,197,241)(H,198,252)(H,199,250)(H,200,262)(H,201,242)(H,202,253)(H,203,254)(H,204,251)(H,205,259)(H,206,260)(H,207,265)(H,208,261)(H,209,263)(H,210,266)(H,211,226)(H,212,255)(H,213,258)(H,214,256)(H,215,257)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H,235,236)(H,237,238)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1 
 | StdInChIKey       = KAIWQAZASNVPLR-QCIJIYAXSA-N 
 }} 
 '''Liraglutide''' (marketed with brand name '''Victoza''') is a [[Type 2 diabetes]] medication. It is a long-acting glucagon like peptide-1 agonist. It was approved by the [[Food and Drug Administration]] in early 2010. 
 
 This medication is a once daily treatment of Type 2 diabetes. 
 
 {{Oral hypoglycemics and insulin analogs}} 
 
 [[Category:Anti-diabetic drugs]] 
 [[Category:Peptides]] 
 
 
 {{med-stub}}